Brief: Aravive Announces Positive Updated Data And New Biomarker Data From Phase 1B Study Of Batiraxcept In Clear Cell Renal Cell Carcinoma

Aravive

03/03/2022 12:55

March 3 (Reuters) - Aravive Inc  ARAV.O :
    * ARAVIVE ANNOUNCES POSITIVE UPDATED DATA AND NEW BIOMARKER
DATA
FROM PHASE 1B STUDY OF BATIRAXCEPT IN CLEAR CELL RENAL CELL
CARCINOMA
    * ARAVIVE - BEST OVERALL RESPONSE RATE AND 6-MONTH
PROGRESSION-FREE SURVIVAL RATE OBSERVED IN PHASE 1B TRIAL OF
BATIRAXCEPT IN PATIENTS WITH CCRCC

Source text for Eikon:  ID:nGNX6893t1 
Further company coverage:  ARAV.O 

 ((Reuters.Briefs@thomsonreuters.com;))